Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

LNCaP cells

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5 alpha Reductase (2) Akt (2) AMPK (1) Androgen Receptor (31) Apoptosis (12) Atg4 (1) Autophagy (5) Bacterial (1) Cannabinoid Receptor (1) Caspase (2) Cathepsin (1) CDK (1) Deubiquitinase (1) Endogenous Metabolite (2) Epigenetic Reader Domain (3) Estrogen Receptor/ERR (1) Fatty Acid Synthase (FASN) (1) Fungal (1) HDAC (3) Histone Acetyltransferase (2) Histone Demethylase (5) Histone Methyltransferase (1) Isotope-Labeled Compounds (2) Ligands for E3 Ligase (1) Ligands for Target Protein for PROTAC (1) MAGL (1) MDM-2/p53 (1) MNK (1) Monoamine Oxidase (3) mTOR (3) NF-κB (1) NO Synthase (1) p38 MAPK (1) PGE synthase (1) Phospholipase (1) PI3K (1) PKC (2) PROTAC Linkers (1) PROTACs (6) Src (1)
By Research Areas:	Cancer (76) Endocrinology (1) Infection (5) Inflammation/Immunology (3) Metabolic Disease (2)

By Targets:

5 alpha Reductase (2)

Akt (2)

AMPK (1)

Androgen Receptor (31)

Apoptosis (12)

Atg4 (1)

Autophagy (5)

Bacterial (1)

Cannabinoid Receptor (1)

Caspase (2)

Cathepsin (1)

CDK (1)

Deubiquitinase (1)

Endogenous Metabolite (2)

Epigenetic Reader Domain (3)

Estrogen Receptor/ERR (1)

Fatty Acid Synthase (FASN) (1)

Fungal (1)

HDAC (3)

Histone Acetyltransferase (2)

Histone Demethylase (5)

Histone Methyltransferase (1)

Isotope-Labeled Compounds (2)

Ligands for E3 Ligase (1)

Ligands for Target Protein for PROTAC (1)

MAGL (1)

MDM-2/p53 (1)

MNK (1)

Monoamine Oxidase (3)

mTOR (3)

NF-κB (1)

NO Synthase (1)

p38 MAPK (1)

PGE synthase (1)

Phospholipase (1)

PI3K (1)

PKC (2)

PROTAC Linkers (1)

PROTACs (6)

Src (1)

By Research Areas:

Cancer (76)

Endocrinology (1)

Infection (5)

Inflammation/Immunology (3)

Metabolic Disease (2)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Nuclear Factor of activated T Cells (NFAT)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-70002

Enzalutamide Maximum Cited Publications 152 Publications Verification MDV3100	Androgen Receptor Autophagy	Cancer
Enzalutamide (MDV3100) is an androgen receptor (AR) antagonist with an IC₅₀ of 36 nM in LNCaP prostate cells. Enzalutamide is an autophagy activator .

HY-70002S1

Enzalutamide-d6 MDV3100-d₆	Androgen Receptor	Cancer
Enzalutamide-d₆ is a deuterium labeled Enzalutamide (MDV3100). Enzalutamide is an androgen receptor (AR) antagonist with an IC50 of 36 nM in LNCaP prostate cells[1].

HY-70002S

Deutenzalutamide Enzalutamide-d₃; MDV3100-d₃	Androgen Receptor Autophagy	Cancer
Deutenzalutamide (Enzalutamide-d₃) is a developed deuterium labeled Enzalutamide (MDV3100). Enzalutamide is an androgen receptor (AR) antagonist with an IC50 of 36 nM in LNCaP prostate cells .

HY-149862

ARD-2051	PROTACs Androgen Receptor	Cancer
ARD-2051 is a potent and orally active androgen receptor (AR) proteolysis-targeting chimera degrader. ARD-2051 achieves DC₅₀ values of 0.6 nM for AR protein degradation in both the LNCaP and VCaP prostate cancer cell lines. ARD-2051 can be used for the research of prostate cancer .

HY-N2908

Atraric acid Methyl atrarate	Androgen Receptor NO Synthase p38 MAPK NF-κB	Inflammation/Immunology Cancer
Atraric acid (Methyl atrarate) is a specific androgen receptor (AR) antagonist with anti-inflammatory and anticancer effects. Atraric acid represses the expression of the endogenous prostate specific antigen gene in both LNCaP and C4-2 cells. Atraric acid can also inhibit the synthesis of NO and cytokine, and suppress the MAPK-NFκB signaling pathway. Atraric acid can be used to research prostate diseases and inflammatory diseases .

HY-70002R

Enzalutamide (Standard)	Androgen Receptor Autophagy	Cancer
Enzalutamide (Standard) is the analytical standard of Enzalutamide. This product is intended for research and analytical applications. Enzalutamide (MDV3100) is an androgen receptor (AR) antagonist with an IC₅₀ of 36 nM in LNCaP prostate cells. Enzalutamide is an autophagy activator .

HY-N10265

Stephacidin B	Endogenous Metabolite	Cancer
Stephacidin B is a fungal metabolite. Stephacidin B shows in vitro cytotoxicity against a panel of human tumor cell lines. Stephacidin B shows the strongest cytotoxicity against testosterone-dependent prostate LNCaP cancer cells .

HY-N2733

7,2',4'-Trihydroxy-5-methoxy-3-arylcoumarin	Others	Others
7,2',4'-Trihydroxy-5-methoxy-3-arylcoumarin is a coumarin, that can be isolated from campylotropis hirtella (FRANCH.) SCHINDL. 7,2',4'-Trihydroxy-5-methoxy-3-arylcoumarin inhibits PSA secretion in LNCaP cells, with an IC₅₀ of 24.2 μg/mL .

HY-144755

MC2652	Histone Demethylase	Cancer
MC2652 (compound 1a) is a potent LSD1 inhibitor. MC2652 displays high inhibiting effects in MV4-11 and NB4 leukaemia cells. MC2652 shows antiproliferative activity against prostate cancer LNCaP cells .

HY-N3816

ent-17-Hydroxykaur-15-en-19-oic acid	Others	Others
ent-17-Hydroxykaur-15-en-19-oic acid is a ent-kaurene diterpene that can be isolated from the leaves of Laetia thamnia L.. ent-17-Hydroxykaur-15-en-19-oic acid was cytotoxic to human prostate LNCaP2 cells with IC₅₀ 17.63 mg/mL .

HY-144756

LSD1-IN-15	Histone Demethylase Monoamine Oxidase	Cancer
LSD1-IN-15 (compound 1b) is a potent LSD1 inhibitor. LSD1-IN-15 can inhibit LSD1-CoREST, MAO-A and MAO-B, with IC₅₀ values of 0.149, 0.028, and 0.327 μM, respectively. LSD1-IN-15 displays cell growth arrest in prostate cancer LNCaP cells, with an IC₅₀ of 9.9 μM .

HY-144757

LSD1-IN-16	Histone Demethylase Monoamine Oxidase	Cancer
LSD1-IN-16 (compound 4b) is a potent LSD1 inhibitor. LSD1-IN-16 can inhibit LSD1-CoREST, MAO-A and MAO-B, with IC₅₀ values of 0.015, 0.024, and 0.366 μM, respectively. LSD1-IN-16 displays cell growth arrest in prostate cancer LNCaP cells, with an IC₅₀ of 15.2 μM .

HY-144758

LSD1-IN-17	Histone Demethylase Monoamine Oxidase	Cancer
LSD1-IN-17 (compound 5b) is a potent LSD1 inhibitor. LSD1-IN-17 can inhibit LSD1-CoREST, MAO-A and MAO-B, with IC₅₀ values of 0.005, 0.028, and 0.820 μM, respectively. LSD1-IN-17 displays cell growth arrest in prostate cancer LNCaP cells, with an IC₅₀ of 17.2 μM .

HY-121619

Jacaric acid	Apoptosis	Inflammation/Immunology Cancer
Jacaric acid is a conjugated linolenic acid, which inhibits viability in cells PC-3 (IC₅₀ is 11.8 μM), LNCaP (IC₅₀ is 2.2 μM) and DLD-1, induces apoptosis and necrosis . Jacaric acid exhibits anticaner activity against prostate cancer and adenocarcinoma . Jacaric acid exhibits immunomodulating activity in murine peritoneal macrophages as an immunopotentiator . Jacaric acid is orally active.

HY-N1342

Rocaglaol	Apoptosis	Cancer
Rocaglaol induces apoptosis and cell cycle arrest in LNCaP cells .

HY-126464

Estromustine EoM	Androgen Receptor	Cancer
Estromustine (EoM) is the active metabolite of Estramustine phosphate (HY-13627A). Estromustine binds to mutant androgen receptor (m-AR) with EC₅₀ of 2.6 μM in LNCaP, exhibits cytotoxicity in human prostate cells LNCaP with IC₅₀ of 9.73 μM .

HY-113332

Myristoleic acid	Apoptosis Endogenous Metabolite	Inflammation/Immunology
Myristoleic acid, a cytotoxic component in the extract from Serenoa repens, induces apoptosis and necrosis in human prostatic LNCaP cells .

HY-N3999

Venuloside A ESK246	Others	Cancer
Venuloside A is a potent inhibitor of LAT3. Venuloside A inhibits the leucine uptake in LNCaP prostate cancer cells with an IC₅₀ of 8.12 μM .

HY-120581

ML388	PGE synthase	Cancer
ML388 is a potent and selective hydroxyprostaglandin dehydrogenase (HPGD) inhibitor with an IC₅₀ of 34 nM. ML388 induces PGE2 production in A549 cells and LNCaP prostate cancer cells .

HY-N8856

Angelol M	Others	Others
Angelol M,isolated from the roots of Angelica gigas Nakai, shows activity in inhibiting prostate specific antigen (PSA) secreted from androgen dependent prostate cancer cell line, LNCaP cells .

HY-163641

AR Degrader-1	Androgen Receptor	Cancer
AR Degrader-1 is an androgen receptor (AR) monovalent degrader. AR Degrader-1 degrades AR without obvious cytotoxicity in LNCaP prostate cancer cells .

HY-N1338

Royleanone NSC 122417	mTOR Akt	Cancer
Royleanone, a diterpenoid isolated from plants, inhibits the proliferation of cancer cells by inducing cell cycle arrest and mitochondria-mediated apoptosis, also inhibits cell migration potential, inhibits mTOR/PI3/AKT signaling pathway in LNCaP prostate cancer cells .

HY-131953

Androgen receptor-IN-3	Androgen Receptor	Cancer
Androgen receptor-IN-3 (Compound 22) is an androgen receptor inhibitor. Androgen receptor-IN-3 inhibits AR-driven transcriptional activity in LNCaP cells, with an IC₅₀ of 5.04 μM .

HY-13626

Spisulosine ES-285	PKC	Cancer
Spisulosine (ES-285) is an antiproliferative (antitumoral) compound of marine origin. Spisulosine inhibits the growth of the prostate PC-3 and LNCaP cells through intracellular ceramide accumulation and PKCζ activation .

HY-N12124

Monascuspiloin Monascinol	Akt mTOR AMPK Androgen Receptor Apoptosis Autophagy	Cancer
Monascuspiloin (Monascinol) exhibits anti-androgenic activity with an IC₅₀ of 7 μM. Monascuspiloin inhibits viability of PC-3 and LNCaP with IC₅₀ of 45 and 47 μM. Monascuspiloin induces apoptosis in LNCaP through inhibition of Akt/mTOR signaling pathway, induces autophagy through activation AMPK signaling pathway and arrest cell cycle at G2/M phase in PC-3. Monascuspiloin exhibits antitumor efficacy in mice .

HY-150268

BET-IN-16	Epigenetic Reader Domain	Cancer
BET-IN-16 (Comp I) is a BET inhibitor. BET-IN-16 shows anticancer activity. BET-IN-16 inhibits prostate cancer cell growth, with IC₅₀ values of 0.043 and 0.034 μM against LNCaP and 22Rv1 cells, respectively .

HY-13626S

Spisulosine-d3	Isotope-Labeled Compounds PKC	Cancer
Spisulosine-d₃ is deuterium labeled Spisulosine. Spisulosine (ES-285) is an antiproliferative (antitumoral) compound of marine origin. Spisulosine inhibits the growth of the prostate PC-3 and LNCaP cells through intracellular ceramide accumulation and PKC

HY-149433

BWA-522	Androgen Receptor Apoptosis	Cancer
BWA-522 is an orally available small molecule protein-targeting chimera (PROTACs) with significant degradation effect on AR-FL and AR-V7. BWA-522 antagonizes the N-terminal domain (AR-NTD) of the androgen receptor (Androgen Receptor) and induces apoptosis in PC cells. BWA-522 inhibits tumor growth in LNCaP xenograft model studies (60 mg/kg, po; TGI=76%). The efficiencies of BWA-522 in degrading AR-V7 and AR-FL were 77.3% (1 μM) and 72.0% (5 μM) in VCaP and LNCaP cells, respectively .

HY-118091A

Bexlosteride LY300502	Others	Cancer
Bexlosteride (LY300502) is a benzoquinolinone human type I 5α-reductase inhibitor. Bexlosteride shows metabolic inhibitory, antiproliferative, and antisecretory effects in LNCaP human prostatic adenocarcinoma cell cultures. Bexlosteride can be used for the research of prostatic cancer .

HY-153772

Androgen receptor antagonist 8	Androgen Receptor	Cancer
Androgen receptor antagonist 8 (Example 13) is an androgen receptor antagonist. Androgen receptor antagonist 8 inhibits prostate specific antigen secretion in LNcap cell (IC₅₀: 88 nM). Androgen receptor antagonist 8 can be used for prostate cancer research .

HY-156778

Antitumor agent-120	Others	Cancer
Antitumor agent-120 (compound 1) is a flavonoid compound isolated from Kudzu root.Antitumor agent-120 has no significant inhibitory activity against LNCaP and PC3 cancer cells, with IC₅₀s >50 μM .

HY-17548

VMY-1-103	Caspase Apoptosis	Cancer
VMY-1-103 is an inhibitor for cyclin/Cdk complex, that arrests the cell cycle at G1 phase. VMY-1-103 reduces mitochondrial membrane potential, induces p53 phosphorylation and and PARP cleavage, activates caspase-3, and thus induces apoptosis in prostate cancer cell LNCaP .

HY-142772

Y08284	Epigenetic Reader Domain	Cancer
Y08284 is a potent, selective, oral active CBP bromodomain inhibitor with an IC50 of 4.21 nM. Y08284 suppresses the proliferation of prostate cancer cell lines LNCaP, C4-2B, and 22Rv1. Antitumor activity .

HY-118375

Phenylbutyl isoselenocyanate ISC-4	Apoptosis	Cancer
Phenylbutyl isoselenocyanate (ISC-4) is a selective apoptosis inducer that increases reactive oxygen species levels to inhibit androgen receptor (AR) and activate p53 pathway. Phenylbutyl isoselenocyanate induces apoptosis in LNCaP prostate cancer cells and has anti-prostate cancer properties.

HY-149914

WCA-814	Androgen Receptor	Cancer
WCA-814 is an androgen receptor (AR) antagonist-Hsp90 inhibitor conjugate. WCA-814 induces the degradation of full-length and AR-V7. WCA-814 has cytotoxic effect in prostatic cancer cells (IC₅₀: 171.2 nM, 26.5 nM for LNCaP, 22Rv1 cell) .

HY-161741

VinclozolinM2-2204	Androgen Receptor	Cancer
VinclozolinM2-2204 is a androgen receptor (AR) degrader, with an DC₅₀ of 200 nM in LNCaP prostate cancer cells. VinclozolinM2-2204 induces the formation of AR ⁺LC3 ⁺ autophagic membranes. VinclozolinM2-2204 can be used for the research of cancer .

HY-164662

mTOR inhibitor-24	mTOR PI3K	Cancer
mTOR inhibitor-24 (comounp 9d) is a mTOR inhibitor, with IC₅₀s of 0.34 nM (mTOR) and 324 nM (PI3K-α) respectively. mTOR inhibitor-24 inhibtis LNCaP cell proliferation (IC₅₀: 180 nM) .

HY-139970

VPC-13789	Androgen Receptor	Endocrinology Cancer
VPC-13789 is a potent, selective, and orally bioavailable antiandrogen. VPC-13789 can be used for the research of castration-resistant prostate cancer (CRPC) therapeutics. VPC-13789 inhibits androgen receptor (AR) transcriptional activity in LNCaP cells (IC₅₀=0.19 μM) .

HY-130992

Androgen receptor antagonist 1	Androgen Receptor Ligands for Target Protein for PROTAC	Cancer
Androgen receptor antagonist 1 is an orally available full androgen receptor (AR) antagonist with an IC₅₀ of 59 nM . Androgen receptor antagonist 1 (Compound 6) can be used in the synthesis of PROTAC AR degraders, which results 24% and 47 % AR protein degradation in LNCaP cells at 1 μM and 10 μM, respectively .

HY-115282A

JNJ-63576253 1 Publications Verification TRC-253	Androgen Receptor	Cancer
JNJ-63576253 (TRC-253) is a potent and orally active full antagonist of androgen receptor (AR), with IC₅₀s of 37 and 54 nM for F877L mutant AR and wild-type AR in LNCaP cells. JNJ-63576253 can be used for the research of castration-resistant prostate cancer (CRPC) .

HY-129672

Thelenotoside B 25-Dihydrostichorrenoside E	Others	Cancer
Thelenotoside B (25-Dihydrostichorrenoside E) shows strong cytotoxicities against five cancer cell lines as HepG2, KB, LNCaP, MCF7 and SK-Mel2 with the IC₅₀ values from 0.95 ± 0.08 to 1.90 ± 0.13 μM. Thelenotoside B is a triterpene tetraglycoside .

HY-169282

RGS2–Galpha-q interaction-IN-1	Others	Cancer
RGS2–Galpha-q interaction-IN-1 (Compound AJ-3) is an inhibitor of the RGS2-G_alpha-q interaction. RGS2–Galpha-q interaction-IN-1 can inhibit the growth of cancer cell lines expressing RGS2 and exhibits anti-cell migration properties .

HY-162794

YCH3124	Apoptosis Deubiquitinase	Cancer
YCH3124 (compound Z33) is a USP7 inhibitor (IC₅₀=41.9 nM) with antitumor activity. YCH3124 has good in vitro antiproliferative activity against various tumor cells including LNCaP (IC₅₀=3.6 nM) and CHP-212 (IC₅₀=9.9 nM). In addition, YCH3124 disrupts cell cycle progression by restricting G1 phase and induces apoptosis in CHP-212 cells .

HY-115282

JNJ-63576253 free base TRC-253 free base	Androgen Receptor	Cancer
JNJ-63576253 (TRC-253) free base is a potent and orally active full antagonist of androgen receptor (AR), with IC₅₀s of 37 and 54 nM for F877L mutant AR and wild-type AR in LNCaP cells. JNJ-63576253 free base can be used for the research of castration-resistant prostate cancer (CRPC) .

HY-144127

AR antagonist 3	Androgen Receptor	Cancer
AR antagonist 3 is a potent and selective androgen receptor (AR) antagonist with an IC₅₀ of 0.47 µM. AR antagonist 3 exhibits a dose-dependent decrease of the FRET signal (IC₅₀= 18.05 μM). AR antagonist 3 shows effective inhibition on tumor growth when administered intratumorally .

HY-152520

RLA-5331	Androgen Receptor	Cancer
RLA-5331 is an iron activator containing anti-androgen. RLA-5331 has anti-proliferative activity on metastatic castration-resistant prostate cancer (mCRPC) cell line .

HY-121094

Androgen receptor allosteric antagonist 1	Estrogen Receptor/ERR	Cancer
Androgen receptor allosteric antagonist 1(compound D36)is a a llosteric, competitive androgen receptor (AR) antagonist with the K_i of 9 μM. Androgen receptor allosteric antagonist 1 inhibits R1881-mediated transcription and proliferation and can be used for study of prostate cancer .

HY-156003

HDAC-IN-64	HDAC	Cancer
HDAC-IN-64 (Compound 13) is a HDAC inhibitor. HDAC-IN-64 inhibits HDAC4/5/6/7/9 with IC₅₀s of 24, 45, 85, 31, 37 nM. HDAC-IN-64 has anti-proliferative activity and anti-migration properties on prostate cancer (PCA) cells. HDAC-IN-64 inhibits LNCaP and RWPE-1 cell growth with GI₅₀ of 0.32 and 1.1 μM respectively .

HY-16079

AZD3514 3 Publications Verification	Androgen Receptor	Cancer
AZD3514 is an orally activie and selective androgen receptor (AR) inhibitor. AZD3514 androgen-dependently and -independently inhibits AR signal. AZD351 down-regulates nuclear AR levels in human LNCaP prostate cancer cells in the absence of androgen with an pIC₅₀ value of 5.75. AZD3514 can be used for the research of prostate cancer .

HY-N7510

12-O-Methylcarnosic acid 12-Methoxycarnosic acid	5 alpha Reductase	Infection Cancer
12-O-Methylcarnosic acid (12-Methoxycarnosic acid), a diterpene carnosic acid isolated from the acetone extract of Salvia microphylla, is an active constituent of 5α-reductase inhibition with an IC₅₀ value of 61.7 μM. 12-O-Methylcarnosic acid inhibits proliferation in LNCaP cells. 12-O-Methylcarnosic acid has antioxidant, anti-cancer and antimicrobial activity .

Cat. No.	Product Name	Category	Target	Chemical Structure